Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.

MedStar author(s):
Citation: Catheterization & Cardiovascular Interventions. 84(7):1053-60, 2014 Dec 1.PMID: 24619969Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Comparative Study | Journal ArticleSubject headings: *Acute Coronary Syndrome/su [Surgery] | *Coronary Restenosis/pc [Prevention & Control] | *Drug-Eluting Stents | *Percutaneous Coronary Intervention/mt [Methods] | *Sirolimus/aa [Analogs & Derivatives] | Acute Coronary Syndrome/di [Diagnosis] | Aged | Antineoplastic Agents | Cause of Death/td [Trends] | Coronary Restenosis/ep [Epidemiology] | Female | Follow-Up Studies | Humans | Immunosuppressive Agents/pd [Pharmacology] | Incidence | Male | Middle Aged | Prosthesis Design | Retrospective Studies | Risk Factors | Sirolimus/pd [Pharmacology] | Time Factors | Treatment Outcome | Washington/ep [Epidemiology]Local holdings: Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006ISSN:
  • 1522-1946
Name of journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & InterventionsAbstract: BACKGROUND: There have been concerns about the long-term safety of drug-eluting stents in the setting of acute coronary syndrome.CONCLUSIONS: There was an improvement in the long-term outcome for MACE with EES when compared to earlier-generation stents, but this was comparable with the 2nd-generation E-ZES. There was no additional risk of early or late stent thrombosis in EES when compared with BMS.Copyright � 2014 Wiley Periodicals, Inc.E-ZES: HR 1.08, 95% CI 0.65-1.77, P=0.72). Stent thrombosis rates were similar for EES, E-ZES, and BMS but higher for SES throughout the 3-year follow-up (EES vs. BMS: HR 1.02, 95% CI: 0.31-3.35, P=0.973; EES vs. SES: HR 4.90, 95% CI: 1.75-13.69, P=0.002 and EES vs.E-ZES: HR 1.63, 95% CI 0.37-7.31, P=0.449).METHODS: The study cohort included 1,612 patients presenting with acute coronary syndrome who underwent BMS, SES, E-ZES, or EES implantation. End points included probable or definite stent thrombosis and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, Q-wave myocardial infarction, and target lesion revascularization up to 3 years.OBJECTIVES: This study aimed to investigate the long-term safety and efficacy of everolimus-eluting stents (EES) compared with other limus-eluting stents and bare metal stents (BMS) in ACS patients.RESULTS: The overall MACE rates were significantly higher for both BMS and SES, but not E-ZES, when compared with EES (EES vs. BMS: HR 2.68, 95% CI 1.91-3.78, P <0.001; EES vs. SES: HR 1.75, 95% CI 1.24-2.47, P=0.001 and EES vs.All authors: Kitabata H, Loh JP, Magalhaes MA, Omar A, Pendyala LK, Pichard AD, Satler LF, Suddath WO, Torguson R, Waksman RDigital Object Identifier: Date added to catalog: 2016-01-13
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 24619969

Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006

BACKGROUND: There have been concerns about the long-term safety of drug-eluting stents in the setting of acute coronary syndrome.

CONCLUSIONS: There was an improvement in the long-term outcome for MACE with EES when compared to earlier-generation stents, but this was comparable with the 2nd-generation E-ZES. There was no additional risk of early or late stent thrombosis in EES when compared with BMS.Copyright � 2014 Wiley Periodicals, Inc.

E-ZES: HR 1.08, 95% CI 0.65-1.77, P=0.72). Stent thrombosis rates were similar for EES, E-ZES, and BMS but higher for SES throughout the 3-year follow-up (EES vs. BMS: HR 1.02, 95% CI: 0.31-3.35, P=0.973; EES vs. SES: HR 4.90, 95% CI: 1.75-13.69, P=0.002 and EES vs.

E-ZES: HR 1.63, 95% CI 0.37-7.31, P=0.449).

METHODS: The study cohort included 1,612 patients presenting with acute coronary syndrome who underwent BMS, SES, E-ZES, or EES implantation. End points included probable or definite stent thrombosis and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, Q-wave myocardial infarction, and target lesion revascularization up to 3 years.

OBJECTIVES: This study aimed to investigate the long-term safety and efficacy of everolimus-eluting stents (EES) compared with other limus-eluting stents and bare metal stents (BMS) in ACS patients.

RESULTS: The overall MACE rates were significantly higher for both BMS and SES, but not E-ZES, when compared with EES (EES vs. BMS: HR 2.68, 95% CI 1.91-3.78, P <0.001; EES vs. SES: HR 1.75, 95% CI 1.24-2.47, P=0.001 and EES vs.

English

Powered by Koha